ArticleFrontiers in microbiology2026
Pathogen distribution, antimicrobial resistance, and gut microbiota dysbiosis in patients with cirrhosis complicated by infection in northwestern China.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Infection is a major complication of liver cirrhosis and is associated with substantial morbidity and mortality. However, regional data on pathogen distribution, antimicrobial resistance patterns, and gut microbiota and metabolic alterations among cirrhotic patients with infection in Northwest China remain limited. This study aimed to characterize these features and explore the associations between gut microbiota, short-chain fatty acids (SCFAs), and clinical inflammatory indices in cirrhotic patients with infection. Methods: We retrospectively analyzed 4,425 hospitalized patients with liver cirrhosis between January 2017 and October 2025, including 1,056 patients with concurrent infections, to characterize pathogen distribution and antimicrobial susceptibility patterns. In addition, a prospectively enrolled subgroup of 86 participants was analyzed for gut microbiota composition and fecal SCFA levels. Gut microbiota was characterized using 16S rRNA gene sequencing, and fecal SCFA concentrations were determined by appropriate analytical methods. The discriminatory ability of inflammatory indices, including the neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and systemic immune-inflammation index (SII), was assessed using receiver operating characteristic (ROC) curve analysis. Results: The most frequently isolated Gram-negative bacteria were Discussion: Our findings provide regional data on pathogen distribution, antimicrobial resistance, gut microbiota alterations, and SCFA profiles among cirrhotic patients with infection in Northwest China. The observed associations between gut microbial dysbiosis, reduced butyrate levels, and inflammatory indices highlight potential links between intestinal microbial alterations and infection in cirrhosis. Further longitudinal, multicenter, and mechanistic studies are needed to determine whether these microbiota and metabolic alterations contribute causally to infection susceptibility and to evaluate their potential clinical relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.